LEGN (Legend Biotech) Quality Rank


LEGN Legend Biotech Corp LEGN
73 GF Score
Price $27.08
GF Value $99.70
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Legend Biotech Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Legend Biotech Quality Rank Related Terms

LEGN
73GF Score
Legend Biotech Corp LEGN
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $27.08 is trading 72.8% below its estimated GF Value™ of $99.70. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Quality Rank:
  • GF Value™: $99.70 vs. price of $27.08 (72.8% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score

Get the complete analysis for LEGN

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.08
Price
$99.70
GF Value